Cytarabine liposomes(CSPC Zhongnuo Pharmaceutical)

N/A

Report date: 2026/01/22 16:41:59

Base Information

Drug NameCytarabine liposomes(CSPC Zhongnuo Pharmaceutical)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA-directed DNA polymerase inhibitorsDNA synthesis inhibitors
TargetsDNA-directed DNA polymerase
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCspc Heibei Zhongrun Pharmaceutiacl Co LtdInstitute Of Hematology & Blood Diseases Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInstitute Of Hematology & Blood Diseases HospitalCspc Heibei Zhongrun Pharmaceutiacl Co Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A